Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ARDTNASDAQ:SHCRNASDAQ:VCYTNASDAQ:WGS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDTArdent Health Partners$13.14-3.0%$13.58$11.31▼$20.72$1.88BN/A393,316 shs267,142 shsSHCRSharecare$1.43$1.43$0.48▼$1.44$531.79M0.512.55 million shsN/AVCYTVeracyte$26.44-0.9%$29.49$19.73▼$47.32$2.07B2.09911,476 shs920,272 shsWGSGeneDx$64.57-2.7%$78.86$24.91▼$117.75$1.84B1.941.11 million shs491,275 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDTArdent Health Partners+1.66%-7.95%-6.88%-2.83%+1,353,999,900.00%SHCRSharecare0.00%0.00%0.00%0.00%+64.25%VCYTVeracyte-4.44%-1.07%-8.94%-15.30%+20.93%WGSGeneDx-5.62%-4.06%+8.93%-32.60%+143.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDTArdent Health Partners3.3016 of 5 stars3.50.00.00.02.40.03.1SHCRSharecareN/AN/AN/AN/AN/AN/AN/AN/AVCYTVeracyte3.9742 of 5 stars4.41.00.04.32.20.00.6WGSGeneDx3.5799 of 5 stars3.42.00.00.01.55.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDTArdent Health Partners 3.00Buy$20.6757.28% UpsideSHCRSharecare 2.00Hold$1.43N/AVCYTVeracyte 2.70Moderate Buy$40.9054.69% UpsideWGSGeneDx 2.75Moderate Buy$86.7534.35% UpsideCurrent Analyst Ratings BreakdownLatest SHCR, ARDT, WGS, and VCYT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025ARDTArdent Health PartnersStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$21.00 ➝ $21.005/15/2025ARDTArdent Health PartnersRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$21.00 ➝ $21.005/15/2025WGSGeneDxGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$88.005/9/2025ARDTArdent Health PartnersGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $18.005/9/2025WGSGeneDxJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$80.005/8/2025VCYTVeracyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $42.005/8/2025VCYTVeracyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $41.005/1/2025WGSGeneDxTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$135.00 ➝ $110.005/1/2025WGSGeneDxWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$105.00 ➝ $78.004/9/2025ARDTArdent Health PartnersGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.004/9/2025ARDTArdent Health PartnersMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $18.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDTArdent Health Partners$6.02B0.31N/AN/AN/A∞SHCRSharecare$445.25M1.19N/AN/A$1.22 per share1.17VCYTVeracyte$463.39M4.47$0.06 per share442.29$14.30 per share1.85WGSGeneDx$330.14M5.58N/AN/A$8.78 per share7.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDTArdent Health Partners$53.90M$1.638.066.70N/AN/AN/AN/A8/13/2025 (Estimated)SHCRSharecare-$128.50M-$0.39N/AN/AN/A-33.64%-22.81%-15.96%N/AVCYTVeracyte-$74.40M$0.41N/A36.72N/A-2.18%3.02%2.80%8/5/2025 (Estimated)WGSGeneDx-$175.77M-$1.41N/A30.89N/A-17.12%3.33%1.69%7/29/2025 (Estimated)Latest SHCR, ARDT, WGS, and VCYT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025ARDTArdent Health Partners$0.21$0.29+$0.08$0.29$1.50 billion$1.50 billion4/30/2025Q1 2025WGSGeneDx$0.11$0.28+$0.17-$0.23$79.90 million$87.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDTArdent Health PartnersN/AN/AN/AN/AN/ASHCRSharecareN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/AWGSGeneDxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDTArdent Health Partners0.781.911.78SHCRSharecareN/A2.022.02VCYTVeracyteN/A5.084.79WGSGeneDx0.252.402.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDTArdent Health PartnersN/ASHCRSharecare35.08%VCYTVeracyteN/AWGSGeneDx61.72%Insider OwnershipCompanyInsider OwnershipARDTArdent Health Partners1.70%SHCRSharecare30.61%VCYTVeracyte1.40%WGSGeneDx29.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDTArdent Health Partners24,200143.04 millionN/AOptionableSHCRSharecare3,352371.88 million258.05 millionOptionableVCYTVeracyte79078.32 million76.49 millionOptionableWGSGeneDx1,20028.53 million19.97 millionOptionableSHCR, ARDT, WGS, and VCYT HeadlinesRecent News About These Companies15,937 Shares in GeneDx Holdings Corp. (NASDAQ:WGS) Bought by Harbor Capital Advisors Inc.June 13 at 3:55 AM | marketbeat.comWGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law FirmJune 12 at 5:54 PM | prnewswire.comRosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation – WGSJune 12 at 4:20 PM | businesswire.comThese 24 Stocks Are Ripe for a Short SqueezeJune 12 at 3:11 PM | schaeffersresearch.comGeneDx (NASDAQ:WGS) Trading Down 3.8% - Here's What HappenedJune 12 at 1:20 PM | marketbeat.comGAMMA Investing LLC Grows Stock Holdings in GeneDx Holdings Corp. (NASDAQ:WGS)June 12 at 3:39 AM | marketbeat.comWGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law FirmJune 11 at 5:27 PM | businesswire.comGeneDx Holdings Corp. (NASDAQ:WGS) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCJune 10 at 3:21 AM | marketbeat.comKevin Feeley Sells 370 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) StockJune 4, 2025 | marketbeat.comInsider Selling: GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells 370 Shares of StockJune 4, 2025 | insidertrades.comBank of America Corp DE Lowers Position in GeneDx Holdings Corp. (NASDAQ:WGS)June 4, 2025 | marketbeat.comWellington Management Group LLP Invests $10.82 Million in GeneDx Holdings Corp. (NASDAQ:WGS)June 3, 2025 | marketbeat.comSquarepoint Ops LLC Sells 34,840 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)June 2, 2025 | marketbeat.comProShare Advisors LLC Buys Shares of 3,598 GeneDx Holdings Corp. (NASDAQ:WGS)June 1, 2025 | marketbeat.comMillennium Management LLC Trims Stock Holdings in GeneDx Holdings Corp. (NASDAQ:WGS)May 31, 2025 | marketbeat.comTidal Investments LLC Reduces Stock Holdings in GeneDx Holdings Corp. (NASDAQ:WGS)May 30, 2025 | marketbeat.comAmeriprise Financial Inc. Acquires New Position in GeneDx Holdings Corp. (NASDAQ:WGS)May 30, 2025 | marketbeat.comGeneDx Holdings Corp. (NASDAQ:WGS) Given Average Rating of "Moderate Buy" by BrokeragesMay 30, 2025 | marketbeat.comWall Street Analysts Predict a 32.62% Upside in GENEDX HOLDINGS (WGS): Here's What You Should KnowMay 29, 2025 | zacks.comPolar Asset Management Partners Inc. Acquires Shares of 13,100 GeneDx Holdings Corp. (NASDAQ:WGS)May 29, 2025 | marketbeat.comDeutsche Bank AG Sells 113,731 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)May 29, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSHCR, ARDT, WGS, and VCYT Company DescriptionsArdent Health Partners NYSE:ARDT$13.14 -0.41 (-3.03%) Closing price 03:59 PM EasternExtended Trading$13.15 +0.01 (+0.08%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardent Health Partners, Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.Sharecare NASDAQ:SHCRSharecare, Inc. operates as a digital healthcare platform company. Its Sharecare platform connects people, patients, providers, employers, health plans, government organizations, and communities that optimize individual and population-wide well-being. The company offers enterprise solutions based on a software-as-a-service model that allows enterprise clients to message, motivate, and manage their populations, as well as measure their population progress; a suite of data and information-driven solutions; and life sciences solutions, which provides members with personalized information, programs, and resources to improve their health and well-being. It also operates RealAge, a platform for health assessment to assess behaviors and existing conditions of its members and provide metric for their physical health. In addition, the company provides secure, automated release of information, audit, and business consulting services to streamline the medical records process for medical facilities. It sells its solutions through direct sales organization and partner relationships. Sharecare, Inc. was founded in 2009 and is headquartered in Atlanta, Georgia.Veracyte NASDAQ:VCYT$26.44 -0.25 (-0.94%) Closing price 04:00 PM EasternExtended Trading$26.44 -0.01 (-0.02%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.GeneDx NASDAQ:WGS$64.57 -1.80 (-2.71%) Closing price 04:00 PM EasternExtended Trading$64.50 -0.07 (-0.12%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
